Fate Therapeutics, Inc.
FATE
$2.44
-$0.06-2.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.38% | 3.59% | -0.38% | 5.34% | 9.44% |
| Total Depreciation and Amortization | -4.73% | -4.73% | -5.08% | -1.56% | -1.65% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.93% | -30.45% | 19.23% | -32.40% | 4.78% |
| Change in Net Operating Assets | 120.00% | -665.31% | 109.33% | 590.41% | 101.36% |
| Cash from Operations | 23.97% | -32.20% | 4.35% | 0.87% | 27.28% |
| Capital Expenditure | 66.53% | 79.95% | 45.89% | -61.75% | -13.88% |
| Sale of Property, Plant, and Equipment | -- | -- | 7,800.00% | -97.54% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -38.57% | -16.65% | 21.78% | 12.68% | -52.52% |
| Cash from Investing | -38.28% | -14.63% | 29.89% | 8.58% | -54.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -31.72% | 86.79% | -- |
| Cash from Financing | -- | -- | -31.72% | 86.79% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.30% | -220.46% | 1,057.89% | 82.92% | -141.41% |